Business Insights: Early Stage Drug Safety Strategies and Risk Management

Examine the potential of emerging technologies and strategies for drug safety evaluation in the earliest stages of discovery and clinical development

"Novel in vivo models are now available including zebrafish screens, which are suited for use at the lead optimization stage or earlier... "

Declining industrial productivity has forced companies urgently to address the areas of drug development that are most likely to lead to the failure of a new compound. Innovations are required that can support the earlier termination of drugs which will be toxic in humans and cause rare events that are unlikely to be identified in clinical trials. Major pharma companies have subsequently begun to implement an array of new technologies for drug safety prediction into the discovery phases of research.

Early Stage Drug Safety Strategies and Risk Management is a new report published by Business Insights that identifies the new predictive technologies which can facilitate the earlier termination of potentially unsuccessful compounds. Emerging approaches in key areas such as hepatotoxicity, nephrotoxicity and cardiotoxicity are examined, and the collaborative efforts of academia and technology developers in driving the discovery of safety predictive methods and biomarkers are reviewed. This report evaluates the latest innovative predictive technologies being introduced into pre-clinical and early clinical development phases and also explores the potential cost savings and challenges associated with their implementation.

Click here to view the seven-page executive summary of this report.

Use this report to:

• Assess key technologies for predicting drug safety in the earliest stages of discovery and clinical development with this report’s comprehensive analysis of emerging approaches across in silico, in vitro and in vivo preclinical technologies. 

• Identify which companies are leading the field in safety prediction for new drugs, understand the strategic implementations of large pharma companies and review the role of public-private consortia in solving key issues within this field of predictive safety. 

• Discover the extent to which predictive safety technologies can provide potential cost savings and improvements in attrition rates and assess the challenges and risks associated with the implementation.
  

• Understand the latest strategies to improve safety evaluation in early clinical development with this report’s analysis of the latest approaches in exploratory and Phase I clinical trials.

Click here to view the seven-page executive summary of this report.